Document is current
Any future updates will be listed below
-
Authors
Kuehn, Michael
LaMori, Joyce
DeMartino, Jessica K.
Mesa-Frias, Marco
Doran, Jason
Korrapati, Lohit
Bhojwani, Rhea
Lefebvre, Patrick
Kirson, Noam
-
Funding
Funding for this research was provided by:
Janssen Scientific Affairs, LLC, United States
- License Information
-
More Information
Article History
Received: 2 December 2021
Accepted: 15 November 2022
First Online: 3 December 2022
Declarations
:
: Not required as the study did not involve any human or animal subjects or patient-level data and as the study is based on primary market research with experts in the infectious disease and vaccine space.
: Not applicable.
: JL, MM and JKD are employees of Janssen Scientific Affairs, LLC and own stock or stock options in Johnson & Johnson. Co-authors MK, JD, LK, RB, PL, and NK are employees of Analysis Group, Inc., a consulting firm that received research support from Janssen Scientific Affairs, LLC to conduct this study.
